Veritas and Cannevert Complete Prestudy Visit of the Puerto Rico …

VANCOUVER, British Columbia, Dec. 29, 2017 (GLOBE NEWSWIRE) — Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt:2VP), (“Veritas” or the “Company”) announces that it has completed a prestudy visit of the Fundación de Investigación (“FDI”) facilities in San Juan, Puerto Rico.  This will be the site where the Company’s research arm, Cannevert Therapeutics Ltd. (“CTL”) will be conducting its first human study of CTL-X, a cannabis strain targeting pain management.

As mentioned in a previous release November 20, 2017, a Letter of Intent (the “LOI”) was signed between CTL and FDI to conduct a human study in two stages. The first stage would use an open label design to look at the feasibility of two doses of CTL-X in 5 subjects while the second stage would use a randomized, double-blind, crossover design to assess one dose of CTL-X against a placebo control strain

... read more at: